ANTI-PD-L1 ANTIBODY AND USE THEREOF

Provided in the present invention are a PD-L1 antibody and a use thereof; the antibody or an active fragment thereof does not block the binding of PD-1 with PD-L1, and specifically targets the IgC-like region of PD-L1. The non-blocking PD-L1 antibody of the present invention can circumvent SPD-L1 to the maximum extent, and has the activity of inducing ADCC/CDC functional effects whilst also having excellent anti-tumour activity.